Reuters Health Information: AbbVie, Enanta drug shows potential in hep C genotype 4 patients
AbbVie, Enanta drug shows potential in hep C genotype 4 patients
Last Updated: 2014-11-11
By Reuters Staff
(Reuters) - AbbVie Inc said its experimental drug ABT-450
that treats genotype 4 hepatitis C showed high response rates in
a mid-stage study in patients who have been considered difficult
The company is developing the drug with Enanta
AbbVie's proposed all-oral antiviral treatment consists of
the fixed-dose combination of ABT-450/ritonavir (150/100mg)
co-formulated with ombitasvir (25mg) dosed once daily,
co-administered with weight-based ribavirin (1000mg or 1200mg in
divided doses twice daily).
The combination of two direct-acting antivirals, each with
distinct mechanisms of action, targets and inhibits specific HCV
proteins in the viral replication process, the company said.
At the American Association for the Study of Liver Diseases
meeting underway in Boston, the company said 100% of the
patients who were given the treatment and had failed previous
treatment with pegylated interferon and ribavirin showed high
response rates at 12 weeks after the treatment.
Genotype 4 variant of the hepatitis C virus is more frequent
in the Middle East and Africa, affecting about 34 million people
across the world.
AbbVie also presented data from another mid-stage study
where patients infected with both genotype 1 hepatitis C and HIV
viruses showed response rates of 93.5% and 90.6% after 12 and 24
weeks post-treatment, respectively.